Listeria as a vaccine vector

Microbes and Infection

Volumn 9, Issue 10, 2007, Pages 1226-1235

  Bruhn, Kevin W ^a   Craft, Noah ^a   Miller, Jeff F ^b  

^a LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer immunotherapy; Listeria monocytogenes; Vaccine vector

Indexed keywords

BACTERIAL VACCINE; BETA GALACTOSIDASE; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GLYCOPROTEIN P 15095; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESOTHELIN; MYELOID DIFFERENTIATION FACTOR 88; NY ESO 1 ANTIGEN; OVALBUMIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN E7; RECOMBINANT GAMMA INTERFERON; RECOMBINANT VACCINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; UNINDEXED DRUG; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BACTERIAL VIRULENCE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG MEGADOSE; GLIOMA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSTIMULATION; INNATE IMMUNITY; INTERFERON PRODUCTION; LISTERIA MONOCYTOGENES; LISTERIOSIS; MACROPHAGE ACTIVATION; MELANOMA; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; VIRUS INFECTION;

ANIMALS; BACTERIAL VACCINES; CANCER VACCINES; GENETIC VECTORS; HUMANS; LISTERIA MONOCYTOGENES; VACCINES; VACCINES, SYNTHETIC;

BACTERIA (MICROORGANISMS); LISTERIA; LISTERIA MONOCYTOGENES;

EID: 34548484137     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2007.05.010     Document Type: Short Survey

References (56)

1. Dussurget O., Pizarro-Cerda J., and Cossart P. Molecular determinants of Listeria monocytogenes virulence. Annu. Rev. Microbiol. 58 (2004) 587-610
2. Hamon M., Bierne H., and Cossart P. Listeria monocytogenes: a multifaceted model. Nat. Rev. Microbiol. 4 (2006) 423-434
3. W. Goebel, Life of Listeria in the cytosol, Microb. Infect. (in press).
4. Flutter B., and Gao B. MHC class I antigen presentation - recently trimmed and well presented. Cell Mol. Immunol. 1 (2004) 22-30
5. Watts C. The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat. Immunol. 5 (2004) 685-692
6. Pamer E.G. Immune responses to Listeria monocytogenes. Nat. Rev. Immunol. 4 (2004) 812-823
7. Zenewicz L.A., Foulds K.E., Jiang J., Fan X., and Shen H. Nonsecreted bacterial proteins induce recall CD8 T cell responses but do not serve as protective antigens. J. Immunol. 169 (2002) 5805-5812
8. Jung S., Unutmaz D., Wong P., Sano G., De los S.K., Sparwasser T., Wu S., Vuthoori S., Ko K., Zavala F., Pamer E.G., Littman D.R., and Lang R.A. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17 (2002) 211-220
9. Pron B., Boumaila C., Jaubert F., Berche P., Milon G., Geissmann F., and Gaillard J.L. Dendritic cells are early cellular targets of Listeria monocytogenes after intestinal delivery and are involved in bacterial spread in the host. Cell Microbiol. 3 (2001) 331-340
10. Shen L., and Rock K.L. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr. Opin. Immunol. 18 (2006) 85-91
11. Bahjat K.S., Liu W., Lemmens E.E., Schoenberger S.P., Portnoy D.A., Dubensky Jr. T.W., and Brockstedt D.G. Cytosolic entry controls CD8+-T-cell potency during bacterial infection. Infect Immun. 74 (2006) 6387-6397
12. E.G. Pamer, The innate and adaptive response to Listeria monocytogenes: a short overview, Microb. Infect. in press.
13. Serbina N.V., Salazar-Mather T.P., Biron C.A., Kuziel W.A., and Pamer E.G. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19 (2003) 59-70
14. Torres D., Barrier M., Bihl F., Quesniaux V.J., Maillet I., Akira S., Ryffel B., and Erard F. Toll-like receptor 2 is required for optimal control of Listeria monocytogenes infection. Infect. Immun. 72 (2004) 2131-2139
15. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., Eng J.K., Akira S., Underhill D.M., and Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410 (2001) 1099-1103
16. Way S.S., Kollmann T.R., Hajjar A.M., and Wilson C.B. Cutting edge: protective cell-mediated immunity to Listeria monocytogenes in the absence of myeloid differentiation factor 88. J. Immunol. 171 (2003) 533-537
17. Lauvau G., Vijh S., Kong P., Horng T., Kerksiek K., Serbina N., Tuma R.A., and Pamer E.G. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 294 (2001) 1735-1739
18. O'Riordan M., Yi C.H., Gonzales R., Lee K.D., and Portnoy D.A. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc. Natl. Acad. Sci. USA 99 (2002) 13861-13866
19. O'Connell R.M., Saha S.K., Vaidya S.A., Bruhn K.W., Miranda G.A., Zarnegar B., Perry A.K., Nguyen B.O., Lane T.F., Taniguchi T., Miller J.F., and Cheng G. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J. Exp. Med. 200 (2004) 437-445
20. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4 (2003) 1009-1015
21. Feng H., Zhang D., Palliser D., Zhu P., Cai S., Schlesinger A., Maliszewski L., and Lieberman J. Listeria-infected myeloid dendritic cells produce IFN-beta, priming T cell activation. J. Immunol. 175 (2005) 421-432
22. Brzoza K.L., Rockel A.B., and Hiltbold E.M. Cytoplasmic entry of Listeria monocytogenes enhances dendritic cell maturation and T cell differentiation and function. J. Immunol. 173 (2004) 2641-2651
23. Opitz B., Puschel A., Beermann W., Hocke A.C., Forster S., Schmeck B., van Laak V., Chakraborty T., Suttorp N., and Hippenstiel S. Listeria monocytogenes activated p38 MAPK and induced IL-8 secretion in a nucleotide-binding oligomerization domain 1-dependent manner in endothelial cells. J. Immunol. 176 (2006) 484-490
24. Kobayashi K.S., Chamaillard M., Ogura Y., Henegariu O., Inohara N., Nunez G., and Flavell R.A. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307 (2005) 731-734
25. Yoshimura K., Jain A., Allen H.E., Laird L.S., Chia C.Y., Ravi S., Brockstedt D.G., Giedlin M.A., Bahjat K.S., Leong M.L., Slansky J.E., Cook D.N., Dubensky T.W., Pardoll D.M., and Schulick R.D. Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res. 66 (2006) 1096-1104
26. Shen H., Slifka M.K., Matloubian M., Jensen E.R., Ahmed R., and Miller J.F. Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity. Proc. Natl. Acad. Sci. USA 92 (1995) 3987-3991
27. Pan Z.K., Ikonomidis G., Lazenby A., Pardoll D., and Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat. Med. 1 (1995) 471-477
28. Jensen E.R., Selvakumar R., Shen H., Ahmed R., Wettstein F.O., and Miller J.F. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J. Virol. 71 (1997) 8467-8474
29. Hussain S.F., and Paterson Y. What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol. Immunother. 54 (2005) 577-586
30. Verch T., Pan Z.K., and Paterson Y. Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect. Immun. 72 (2004) 6418-6425
31. Lauer P., Chow M.Y., Loessner M.J., Portnoy D.A., and Calendar R. Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors. J. Bacteriol. 184 (2002) 4177-4186
32. Paterson Y., and Johnson R.S. Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens. Expert Rev. Vaccines 3 (2004) S119-S134
33. Soussi N., Milon G., Colle J.H., Mougneau E., Glaichenhaus N., and Goossens P.L. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major. Infect. Immun. 68 (2000) 1498-1506
34. Scheurer M.E., Tortolero-Luna G., and Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. Int. J. Gynecol. Cancer 15 (2005) 727-746
35. Singh R., and Paterson Y. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy. Expert Rev. Vaccines 5 (2006) 541-552
36. Liau L.M., Jensen E.R., Kremen T.J., Odesa S.K., Sykes S.N., Soung M.C., Miller J.F., and Bronstein J.M. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res. 62 (2002) 2287-2293
37. Vanderlugt C.L., and Miller S.D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2 (2002) 85-95
38. Butterfield L.H., Ribas A., Dissette V.B., Amarnani S.N., Vu H.T., Oseguera D., Wang H.J., Elashoff R.M., McBride W.H., Mukherji B., Cochran A.J., Glaspy J.A., and Economou J.S. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 9 (2003) 998-1008
39. Platsoucas C.D., Fincke J.E., Pappas J., Jung W.J., Heckel M., Schwarting R., Magira E., Monos D., and Freedman R.S. Immune responses to human tumors: development of tumor vaccines. Anticancer Res. 23 (2003) 1969-1996
40. Disis M.L., and Cheever M.A. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res. 71 (1997) 343-371
41. Singh R., Dominiecki M.E., Jaffee E.M., and Paterson Y. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J. Immunol. 175 (2005) 3663-3673
42. Singh R., and Paterson Y. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines. Cancer Immunol. Immunother. 56 (2007) 927-938
43. Bruhn K.W., Craft N., Nguyen B.D., Yip J., and Miller J.F. Characterization of anti-self CD8 T-cell responses stimulated by recombinant Listeria monocytogenes expressing the melanoma antigen TRP-2. Vaccine 23 (2005) 4263-4272
44. Starks H., Bruhn K.W., Shen H., Barry R.A., Dubensky T.W., Brockstedt D., Hinrichs D.J., Higgins D.E., Miller J.F., Giedlin M., and Bouwer H.G. Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J. Immunol. 173 (2004) 420-427
45. Prins R.M., Bruhn K.W., Craft N., Lin J.W., Kim C.H., Odesa S.K., Miller J.F., and Liau L.M. Central nervous system tumor immunity generated by a recombinant Listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden. Neurosurgery 58 (2006) 169-178
46. Craft N., Bruhn K.W., Nguyen B.D., Prins R., Lin J.W., Liau L.M., and Miller J.F. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J. Immunol. 175 (2005) 1983-1990
47. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., and Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6 (2005) 769-776
48. Wilson N.S., Behrens G.M., Lundie R.J., Smith C.M., Waithman J., Young L., Forehan S.P., Mount A., Steptoe R.J., Shortman K.D., Koning-Ward T.F., Belz G.T., Carbone F.R., Crabb B.S., Heath W.R., and Villadangos J.A. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7 (2006) 165-172
49. Mercado R., Vijh S., Allen S.E., Kerksiek K., Pilip I.M., and Pamer E.G. Early programming of T cell populations responding to bacterial infection. J. Immunol. 165 (2000) 6833-6839
50. Angelakopoulos H., Loock K., Sisul D.M., Jensen E.R., Miller J.F., and Hohmann E.L. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect. Immun. 70 (2002) 3592-3601
51. Brockstedt D.G., Giedlin M.A., Leong M.L., Bahjat K.S., Gao Y., Luckett W., Liu W., Cook D.N., Portnoy D.A., and Dubensky Jr. T.W. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. USA 101 (2004) 13832-13837
52. Li Z., Zhao X., Higgins D.E., and Frankel F.R. Conditional lethality yields a new vaccine strain of Listeria monocytogenes for the induction of cell-mediated immunity. Infect. Immun. 73 (2005) 5065-5073
53. Zhao X., Li Z., Gu B., and Frankel F.R. Pathogenicity and immunogenicity of a vaccine strain of Listeria monocytogenes that relies on a suicide plasmid to supply an essential gene product. Infect. Immun. 73 (2005) 5789-5798
54. Brockstedt D.G., Bahjat K.S., Giedlin M.A., Liu W., Leong M., Luckett W., Gao Y., Schnupf P., Kapadia D., Castro G., Lim J.Y., Sampson-Johannes A., Herskovits A.A., Stassinopoulos A., Bouwer H.G., Hearst J.E., Portnoy D.A., Cook D.N., and Dubensky Jr. T.W. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat. Med. 11 (2005) 853-860
55. Stevens R., Lavoy A., Nordone S., Burkhard M., and Dean G.A. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine. Vaccine 23 (2005) 1479-1490
56. + T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 11 (2005) 748-756